Laxminath Tumburu

Laxminath Tumburu

Auto-generated profile, based on publicly available information

Laxminath Tumburu

Sickle Cell Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2021 in Blood
Verified
Journal Article
Open access
PDF file
LTLaxminath Tumburu
Laxminath Tumburu
SGShohini Ghosh-Choudhary
Shohini Ghosh-Choudhary
FSFayaz Seifuddin
Fayaz Seifuddin
EBEmilia A. Barbu
Emilia A. Barbu
SYSimon Yang
Simon Yang
STSwee Lay Thein
Swee Lay Thein
The pathophysiology of sickle cell disease (SCD) is driven by chronic inflammation fueled by damage associated molecular patterns (DAMPs). We show that elevated cell-free DNA (cfDNA) in patients with SCD is not just a prognostic biomarker, it also contributes to the pathological inflammation. Within the elevated cfDNA, patients with SCD had a significantly higher ratio of cell-free mitochondrial DNA (cf-mtDNA)/cell-free nuclear DNA compared with healthy controls. Additionally, mitochondrial DNA in patient samples showed significantly disproportionately increased hypomethylation compared with healthy controls, and it was increased further in crises compared with steady-state. Using flow cytometry, structured illumination microscopy, and electron microscopy, we showed that circulating SCD red blood cells abnormally retained their mitochondria and, thus, are likely to be the source of the elevated cf-mtDNA in patients with SCD. Patient plasma containing high levels of cf-mtDNA triggered the formation of neutrophil extracellular traps (NETs) that was substantially reduced by inhibition of TANK-binding kinase 1, implicating activation of the cGAS-STING pathway. cf-mtDNA is an erythrocytic DAMP, highlighting an underappreciated role for mitochondria in sickle pathology. These trials were registered at www.clinicaltrials.gov as #NCT00081523, #NCT03049475, and #NCT00047996.

10 November 2022 in Blood
Verified
Journal Article
Open access
PDF file
JXJulia Z. Xu
Julia Z. Xu
ACAnna Conrey
Anna Conrey
IFIngrid Frey
Ingrid Frey
EGEveline Gwaabe
Eveline Gwaabe
LMLaurel A. Menapace
Laurel A. Menapace
STSwee Lay Thein
Swee Lay Thein
Polymerization of deoxygenated hemoglobin S underlies the pathophysiology of sickle cell disease (SCD). In activating red blood cell pyruvate kinase and glycolysis, mitapivat (AG-348) increases adenosine triphosphate (ATP) levels and decreases the 2,3-diphosphoglycerate (2,3-DPG) concentration, an upstream precursor in glycolysis. Both changes have therapeutic potential for patients with SCD. Here, we evaluated the safety and tolerability of multiple ascending doses of mitapivat in adults with SCD with no recent blood transfusions or changes in hydroxyurea or l-glutamine therapy. Seventeen subjects were enrolled; 1 subject was withdrawn shortly after starting the study. Sixteen subjects completed 3 ascending dose levels of mitapivat (5, 20, and 50 mg, twice daily [BID]) for 2 weeks each; following a protocol amendment, the dose was escalated to 100 mg BID in 9 subjects. Mitapivat was well tolerated at all dose levels, with the most common treatment-emergent adverse events (AEs) being insomnia, headache, and hypertension. Six serious AEs (SAEs) included 4 vaso-occlusive crises (VOCs), non–VOC-related shoulder pain, and a preexisting pulmonary embolism. Two VOCs occurred during drug taper and were possibly drug related; no other SAEs were drug related. Mean hemoglobin increase at the 50 mg BID dose level was 1.2 g/dL, with 9 of 16 (56.3%) patients achieving a hemoglobin response of a ≥1 g/dL increase compared with baseline. Mean reductions in hemolytic markers and dose-dependent decreases in 2,3-DPG and increases in ATP were also observed. This study provides proof of concept that mitapivat has disease-modifying potential in patients with SCD. This trial was registered at www.clinicaltrials.gov as #NCT04000165.

15 April 2021 in Nature Genetics
Verified
Journal Article
Open access
PDF file
LTLaxminath Tumburu
Laxminath Tumburu
STSwee Lay Thein
Swee Lay Thein
The nucleosome remodeling and deacetylase (NuRD) complex is a chromatin modifier with a key role in the switch from fetal to adult hemoglobin. In a new study, Vinjamur et al. identify a fetal hemoglobin repressor, ZNF410, which does not directly bind the γ-globin promoter but acts through highly specific regulation of CHD4, a protein subunit of the NuRD complex, thus presenting a potential approach for therapeutic reactivation of fetal hemoglobin.

2 November 2023 in Blood
Verified
Journal Article
Open access
LKLe Kang
Le Kang
ZQZena Quezado
Zena Quezado
SKSayuri Kamimura
Sayuri Kamimura
MSMeghann L. Smith
Meghann L. Smith
YTYuki Tahara
Yuki Tahara
STSwee Lay Thein
Swee Lay Thein
Disclosures. No relevant conflicts of interest to declare.Figure 1